SAN DIEGO, CA--(Marketwire - February 25, 2013) -
Drs. Muller, Hentschel, Gilman and Farahati will be presenting their data on 68 women with breast lesions found to be suspicious on mammography, which were then evaluated with positron emission mammography (PEM) using the Naviscan, Inc. high-resolution, organ-specific PET scanner. The presentation, titled 'Positron Emission Mammography Is an Accurate Tool in Diagnosis of Breast Cancer,' will be available on EPOS™ - Electronic Presentation Online System for the 2013 European Congress of Radiology to be held March 7 - 11 in Vienna, Austria.
Of the 70 lesions seen on the mammograms, PEM correctly identified all 14 malignancies when an uptake threshold, known as PUVmax, of greater than 2.0 was used. This resulted in a cancer detection sensitivity of 100%, specificity of 94%, a Positive Predictive Value (PPV) of 89%, and Negative Predictive Value (NPV) of 100%. Both PPV and NPV are measure of the modality's accuracy.
The average lesion to background ratio of FDG uptake was 3.4+/-1.6 for cancerous lesions and 1.1+/-0.02 for benign lesions, a statistically significant difference (p=0.001). This pilot study demonstrated that by using PEM and FDG quantitative analysis, breast cancer can be differentiated from benign breast lesions with extremely high accuracy, thereby potentially saving unnecessary biopsies of benign lesions.
About Naviscan PEM Scanner
The Naviscan PEM scanner is compact, mobile and easy-to-use for precisely characterizing breast cancer, enhancing surgical planning, monitoring patient response to chemotherapy and evaluating suspected recurrence. It is designed to show the metabolic phase of a lesion allowing for early breast cancer diagnosis and assisting physicians in making optimal care decisions by providing an ability to distinguish between benign and malignant lesions.
About Naviscan, Inc.
Naviscan, founded in 1995, develops and markets compact, high-resolution PET scanners intended to provide organ-specific molecular imaging and guide radiological and surgical procedures. The Naviscan PET scanner is currently installed and available in breast and imaging centers throughout the world with global distribution in 34 countries. The Company is headquartered in San Diego, California and is the first to obtain FDA clearance and CE Mark for a high-resolution PET scanner designed to image small body parts and for breast biopsy image guidance. For more information, visit www.naviscan.com.